Episode
E133: Obinutuzumab for SLE (ALLEGORY)
- Published
- Mar 19, 2026
- Duration seconds
- 921
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e133-obinutuzumab-for-sle-allegory/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e133-obinutuzumab-for-sle-allegory.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150 Landing Page: https://ebrheum.com/ Substack: https://autoimmunedevreport.substack.com/